ATE223718T1 - Verwendung von riminophenazin zur behandlung von mdr-resistenz - Google Patents

Verwendung von riminophenazin zur behandlung von mdr-resistenz

Info

Publication number
ATE223718T1
ATE223718T1 AT95301772T AT95301772T ATE223718T1 AT E223718 T1 ATE223718 T1 AT E223718T1 AT 95301772 T AT95301772 T AT 95301772T AT 95301772 T AT95301772 T AT 95301772T AT E223718 T1 ATE223718 T1 AT E223718T1
Authority
AT
Austria
Prior art keywords
alkyl
hydrogen
riminophenazine
halogen atom
riminophenazines
Prior art date
Application number
AT95301772T
Other languages
English (en)
Inventor
Constance Elizabeth Medlen
Ronald Anderson
John Francis O'sullivan
Original Assignee
Univ Pretoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pretoria filed Critical Univ Pretoria
Application granted granted Critical
Publication of ATE223718T1 publication Critical patent/ATE223718T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Paper (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Glass Compositions (AREA)
  • Silicon Polymers (AREA)
AT95301772T 1994-04-05 1995-03-16 Verwendung von riminophenazin zur behandlung von mdr-resistenz ATE223718T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA942363 1994-04-05
ZA949352 1994-11-24

Publications (1)

Publication Number Publication Date
ATE223718T1 true ATE223718T1 (de) 2002-09-15

Family

ID=66553352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95301772T ATE223718T1 (de) 1994-04-05 1995-03-16 Verwendung von riminophenazin zur behandlung von mdr-resistenz

Country Status (7)

Country Link
EP (1) EP0676201B1 (de)
JP (1) JPH07277982A (de)
KR (1) KR950031076A (de)
AT (1) ATE223718T1 (de)
AU (1) AU696324B2 (de)
CA (1) CA2144783A1 (de)
DE (1) DE69528103T2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP603A (en) * 1995-01-31 1997-07-28 Univ Van Pretoria A method of treating malaria by administering a product containing reminophenazine.
KR970704704A (ko) * 1995-05-22 1997-09-06 오쓰카 아키히코 디하이드로펜아진 유도체, 이의 제조 방법, 및 결핵균 및 비정형 항산균용 약물(Dihydrophenazine derivative, process for producing the same and drug for tubercle bacilli and atypical acid-fast bacilli)
AU2908997A (en) * 1996-05-24 1998-01-05 University Of Pretoria, The Use of riminophenazines as antimicrobial and antimalarial agents
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6387902B1 (en) * 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
AU2001275085A1 (en) 2000-06-01 2001-12-11 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
AUPR644301A0 (en) * 2001-07-17 2001-08-09 Unisearch Limited Method and composition for treatment of cancer
JP2016164125A (ja) * 2013-07-02 2016-09-08 国立大学法人帯広畜産大学 バベシア症の治療剤及び予防剤
CN107382882B (zh) * 2017-07-26 2022-03-25 浙江华海药业股份有限公司 一种氯法齐明的精制方法

Also Published As

Publication number Publication date
AU696324B2 (en) 1998-09-10
JPH07277982A (ja) 1995-10-24
EP0676201A2 (de) 1995-10-11
DE69528103T2 (de) 2003-05-15
EP0676201B1 (de) 2002-09-11
EP0676201A3 (de) 1996-06-12
CA2144783A1 (en) 1995-10-06
KR950031076A (ko) 1995-12-18
AU1498295A (en) 1995-10-12
DE69528103D1 (de) 2002-10-17

Similar Documents

Publication Publication Date Title
ATE223718T1 (de) Verwendung von riminophenazin zur behandlung von mdr-resistenz
NO161910C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetralinderivater.
DE69922216D1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
ATE384524T1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
EP0948327A4 (de) Antidiabetische mittel
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
NO872382L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
NZ217418A (en) Tricyclic heterocyclic compounds and pharmaceutical compositions
ATE121395T1 (de) Cumarinderivate, ihre herstellung und ihre verwendung zur behandlung von zerebrovaskulären störungen.
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
JPS5716841A (en) Novel compound,manufacture,bactericidal composition and use
ES528461A0 (es) Procedimiento de preparacion de nuevos derivados carbamiloxibenzoles
ATE153340T1 (de) Cyathane derivate und diese enthaltende nervenwachstumsfaktor produktion stimulatoren und antimikrobielle mittel
BG103395A (en) Derivatives of benzenesulphonamide and medicaments containing them
ES8604843A1 (es) Un metodo para la preparacion de un derivado de acetileno
ATE220065T1 (de) Benzopyranderivate und ihre verwendung zur behandlung von herzkrankheiten
NO872874L (no) Amid-derivater.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
ATE64095T1 (de) Verwendung von imidazochinazolinen zur behandlung und verhinderung von nephritis.
ATE95697T1 (de) Uricosuretische zusammensetzung.
JO1599B1 (en) Therapeutic agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties